Diez-Martin J L, Graham D L, Petitt R M, Dewald G W
Cytogenetics Laboratory, Mayo Clinic, Rochester, MN 55905.
Mayo Clin Proc. 1991 Mar;66(3):287-99. doi: 10.1016/s0025-6196(12)61011-8.
Chromosome studies were done in 104 patients with various stages of polycythemia vera (PV): 10 had leukemia-myelodysplastic syndrome, 28 had post-PV with myeloid metaplasia (PPVMM), 12 had PV with myelofibrosis, and 54 had PV. Chromosome studies were successful in 86 patients, 37 (43%) of whom had a chromosome abnormality. At diagnosis, 4 of 28 patients (14%) had an abnormal clone; the incidence was 78% in PPVMM and 100% in leukemia-myelodysplastic syndrome. Among the 63 patients with successful chromosome studies during the first 10 years of disease, 27% had an abnormal clone. In contrast, of the 23 patients who had the disease for more than 10 years, 87% had an abnormal clone. Chromosome abnormalities were found in 11 of the 60 patients who either were untreated or underwent only phlebotomy and in 26 of the 44 patients who were treated with myelosuppressive agents. Trisomy 8, +9, and 20q- were found in some patients early during the course of their disease and also among untreated patients. These chromosome abnormalities seem to be related to the natural course of PV rather than to therapy. Patients with a chromosomally abnormal clone at the time of diagnosis of PV had a poorer survival than did those with only normal metaphases. Cytogenetic results did not predict evolution of the disease, but they did provide clues to hematologic phenotype, duration of the disease, and consequences of myelosuppressive therapy.
对104例不同阶段的真性红细胞增多症(PV)患者进行了染色体研究:10例患有白血病-骨髓增生异常综合征,28例患有真性红细胞增多症后骨髓化生(PPVMM),12例患有PV伴骨髓纤维化,54例患有PV。86例患者的染色体研究成功,其中37例(43%)存在染色体异常。诊断时,28例患者中有4例(14%)存在异常克隆;PPVMM中的发生率为78%,白血病-骨髓增生异常综合征中的发生率为100%。在疾病的前10年中染色体研究成功的63例患者中,27%存在异常克隆。相比之下,在病程超过10年的23例患者中,87%存在异常克隆。在60例未接受治疗或仅接受放血治疗的患者中,有11例发现染色体异常,在44例接受骨髓抑制药物治疗的患者中,有26例发现染色体异常。在一些患者疾病早期以及未治疗患者中发现了8号三体、+9和20q-。这些染色体异常似乎与PV的自然病程有关,而非与治疗有关。PV诊断时存在染色体异常克隆的患者比仅具有正常中期分裂相的患者生存率更低。细胞遗传学结果不能预测疾病的演变,但确实为血液学表型、疾病持续时间和骨髓抑制治疗的后果提供了线索。